Edgestream Partners L.P. Invests $125,000 in Sotera Health (NASDAQ:SHC)

Edgestream Partners L.P. purchased a new stake in shares of Sotera Health (NASDAQ:SHC) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,538 shares of the company’s stock, valued at approximately $125,000.

A number of other hedge funds also recently bought and sold shares of the business. CWM LLC boosted its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after buying an additional 993 shares during the last quarter. Swiss National Bank grew its position in Sotera Health by 0.5% in the first quarter. Swiss National Bank now owns 195,900 shares of the company’s stock worth $2,353,000 after acquiring an additional 1,000 shares in the last quarter. TD Asset Management Inc grew its position in Sotera Health by 1.5% in the second quarter. TD Asset Management Inc now owns 123,454 shares of the company’s stock worth $1,465,000 after acquiring an additional 1,800 shares in the last quarter. Securian Asset Management Inc. grew its position in Sotera Health by 23.0% in the first quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock worth $122,000 after acquiring an additional 1,900 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its position in shares of Sotera Health by 20.6% during the first quarter. State of Alaska Department of Revenue now owns 13,490 shares of the company’s stock valued at $162,000 after buying an additional 2,300 shares during the period. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Insider Activity

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the sale, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 55.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SHC. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Barclays boosted their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.70.

Sotera Health Trading Down 0.1 %

SHC stock opened at $16.64 on Tuesday. The company’s 50-day simple moving average is $14.96 and its 200-day simple moving average is $12.86. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The firm has a market cap of $4.71 billion, a P/E ratio of 87.58 and a beta of 2.07.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Monday, August 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.04. The firm had revenue of $277.00 million during the quarter, compared to the consensus estimate of $266.45 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS. As a group, equities analysts forecast that Sotera Health will post 0.64 EPS for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.